| 0.5698 0.009 (1.59%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.8  |
1-year : | 0.94 |
| Resists | First : | 0.68 |
Second : | 0.81 |
| Pivot price | 0.55 |
|||
| Supports | First : | 0.48 | Second : | 0.4 |
| MAs | MA(5) : | 0.54  |
MA(20) : | 0.57 |
| MA(100) : | 0.52 |
MA(250) : | 0.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 36.8 |
D(3) : | 27.5 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 2.3 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PSTV ] has closed below upper band by 42.9%. Bollinger Bands are 51.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.59 |
| Low: | 0.53 - 0.54 | 0.54 - 0.54 |
| Close: | 0.57 - 0.57 | 0.57 - 0.57 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Thu, 06 Nov 2025
Plus Therapeutics, Inc. (PSTV) Stock: Drops Despite Promising REYOBIQ Clinical Results Highlighted at SITC 2025 - parameter.io
Thu, 06 Nov 2025
Plus Therapeutics (NASDAQ:PSTV) Highlights ReSPECT-LM Trial Results at SITC Annual Meeting - Kalkine Media
Thu, 06 Nov 2025
Plus Therapeutics Stock (PSTV) Opinions on UnitedHealthcare Coverage Agreement - Quiver Quantitative
Thu, 06 Nov 2025
Plus Therapeutics (Nasdaq: PSTV) highlights no DLTs to 44.1 mCi in Phase 1 LM trial - Stock Titan
Thu, 30 Oct 2025
Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq
Tue, 21 Oct 2025
Plus Therapeutics (NASDAQ: PSTV) opens Houston lab as CNSide expands; UHC coverage for 51M - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 1,940 (K) |
| Shares Short P.Month | 4,070 (K) |
| EPS | -1.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.02 |
| Profit Margin | 0 % |
| Operating Margin | -110.7 % |
| Return on Assets (ttm) | -74.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 8.6 % |
| Gross Profit (p.s.) | -0.03 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.41 |
| PEG Ratio | 0 |
| Price to Book value | 18.99 |
| Price to Sales | 10.63 |
| Price to Cash Flow | -3.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|